Academia Urges More Transparency on Labels - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Academia Urges More Transparency on Labels


ePT--the Electronic Newsletter of Pharmaceutical Technology

Researchers from the Stanford University School of Medicine in California are urging the US Food and Drug Administration to demand that drug manufacturers state how new medications compare with similar treatments on product labels. "In many instances, these statements would indicate that there is no evidence that a new drug is more effective than older ones," according to a Stanford news release.

Stafford and his fellow researchers published an essay on the subject in the New England Journal of Medicine. They recommend that FDA require new drugs to carry a label that says, for example: "Although this drug has been shown to lower blood pressure more effectively than placebo, it has not been shown to be more effective than other members of the same drug class." The researchers believe that "developing more informative labels is consistent with the agency's recently invigorated function as a public health agency." (see back story, A Fresh Perspective at FDA.)

The researchers believe that making such information available may influence the decisions made by patients and healthcare insurers. New drugs are often more expensive than existing therapies and may be no more effective. "The public's appetite for the latest drugs might be curbed if patients understood that new treatments aren't necessarily more effective than existing ones," explained the news release.

"Drug and device manufacturers benefit from an unacknowledged information gap that develops as more and more products are tested against placebo, but not each other," said Randell Stafford, associate professor of medicine at the Stanford Prevention Research Center, in the release.

Stephanie Sutton is an assistant editor with PharmTech Europe.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here